Advances in indoleamine 2, 3-dioxygenase 1 medicinal chemistry. Issue 7 (13th June 2017)

• Record Type: Journal Article
• Authors: Coletti, Alice; Greco, Francesco Antonio; Dolciami, Daniela; Camaioni, Emidio; Sardella, Roccaldo; Pallotta, Maria Teresa; Volpi, Claudia; Orabona, Ciriana; Grohmann, Ursula; Macchiarulo, Antonio
• Is Part Of: MedChemComm. Volume 8:Issue 7(2017)
• Page Start: 1378
• Page End: 1392
• Publication Date: 2017-06-13
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c7md00109f
• Languages: English
• ISSNs: 2040-2503

Abstract

Abstract : Structure–function relationships of IDO1 and structure–activity relationships of inhibitors are discussed with an outlook on next generation IDO1 ligand. Abstract : Indoleamine 2, 3-dioxygenase 1 (IDO1) mediates multiple immunoregulatory processes including the induction of regulatory T cell differentiation and activation, suppression of T cell immune responses and inhibition of dendritic cell function, which impair immune recognition of cancer cells and promote tumor growth. On this basis, this enzyme is widely recognized as a valuable drug target for the development of immunotherapeutic small molecules in oncology. Although medicinal chemistry has made a substantial contribution to the discovery of numerous chemical classes of potent IDO1 inhibitors in the past 20 years, only very few compounds have progressed in clinical trials. In this review, we provide an overview of the current understanding of structure–function relationships of the enzyme, and discuss structure–activity relationships of selected classes of inhibitors that have shaped the hitherto few successes of IDO1 medicinal chemistry. An outlook opinion is also given on trends in the design of next generation inhibitors of the enzyme.